Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17021308 | 0.92 | STAT6 (0.51) | STAT6PIK3CBPIK3CACCNT1CDK9 | |
| SCHEMBL19010269 | 0.86 | STAT6 (0.57) | STAT6CCNT1CDK9NTRK1SRC | |
| SCHEMBL19010314 | 0.85 | STAT6 (0.52) | STAT6CCNT1CDK9NTRK1SRC | |
| SCHEMBL19010302 | 0.83 | MAPK10 (0.47) | STAT6CCNT1CDK9NTRK1JAK2 | |
| SCHEMBL19010295 | 0.81 | KCNH2 (0.45) | STAT6NTRK1JAK2 | |
| SCHEMBL19010321 | 0.81 | NTRK1 (0.59) | STAT6NTRK1JAK2 | |
| SCHEMBL19010286 | 0.78 | STAT6 (0.55) | STAT6NTRK1JAK2 | |
| SCHEMBL17021288 | 0.78 | STAT6 (0.63) | STAT6NTRK1SRCJAK2 | |
| SCHEMBL19010318 | 0.78 | NTRK1 (0.46) | STAT6CCNT1CDK9NTRK1SRC | |
| SCHEMBL19010276 | 0.77 | GFER (0.54) | STAT6NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | STAT6 8/4885PIK3CB 358/4885PIK3CA 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.